247 related articles for article (PubMed ID: 24258712)
1. Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.
Shima H; Yamagata K; Aikawa Y; Shino M; Koseki H; Shimada H; Kitabayashi I
Int J Hematol; 2014 Jan; 99(1):21-31. PubMed ID: 24258712
[TBL] [Abstract][Full Text] [Related]
2. MOZ is critical for the development of MOZ/MLL fusion-induced leukemia through regulation of Hoxa9/Meis1 expression.
Katsumoto T; Ogawara Y; Yamagata K; Aikawa Y; Goitsuka R; Nakamura T; Kitabayashi I
Blood Adv; 2022 Oct; 6(19):5527-5537. PubMed ID: 35947126
[TBL] [Abstract][Full Text] [Related]
3. Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes.
Ullah M; Pelletier N; Xiao L; Zhao SP; Wang K; Degerny C; Tahmasebi S; Cayrou C; Doyon Y; Goh SL; Champagne N; Côté J; Yang XJ
Mol Cell Biol; 2008 Nov; 28(22):6828-43. PubMed ID: 18794358
[TBL] [Abstract][Full Text] [Related]
4. Recognition of unmodified histone H3 by the first PHD finger of bromodomain-PHD finger protein 2 provides insights into the regulation of histone acetyltransferases monocytic leukemic zinc-finger protein (MOZ) and MOZ-related factor (MORF).
Qin S; Jin L; Zhang J; Liu L; Ji P; Wu M; Wu J; Shi Y
J Biol Chem; 2011 Oct; 286(42):36944-55. PubMed ID: 21880731
[TBL] [Abstract][Full Text] [Related]
5. Molecular insights into the recognition of N-terminal histone modifications by the BRPF1 bromodomain.
Poplawski A; Hu K; Lee W; Natesan S; Peng D; Carlson S; Shi X; Balaz S; Markley JL; Glass KC
J Mol Biol; 2014 Apr; 426(8):1661-76. PubMed ID: 24333487
[TBL] [Abstract][Full Text] [Related]
6. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP.
Deguchi K; Ayton PM; Carapeti M; Kutok JL; Snyder CS; Williams IR; Cross NC; Glass CK; Cleary ML; Gilliland DG
Cancer Cell; 2003 Mar; 3(3):259-71. PubMed ID: 12676584
[TBL] [Abstract][Full Text] [Related]
7. Expression of the MOZ-TIF2 oncoprotein in mice represses senescence.
Largeot A; Perez-Campo FM; Marinopoulou E; Lie-a-Ling M; Kouskoff V; Lacaud G
Exp Hematol; 2016 Apr; 44(4):231-7.e4. PubMed ID: 26854485
[TBL] [Abstract][Full Text] [Related]
8. MOZ fusion proteins in acute myeloid leukaemia.
Troke PJ; Kindle KB; Collins HM; Heery DM
Biochem Soc Symp; 2006; (73):23-39. PubMed ID: 16626284
[TBL] [Abstract][Full Text] [Related]
9. The multidomain protein Brpf1 binds histones and is required for Hox gene expression and segmental identity.
Laue K; Daujat S; Crump JG; Plaster N; Roehl HH; ; Kimmel CB; Schneider R; Hammerschmidt M
Development; 2008 Jun; 135(11):1935-46. PubMed ID: 18469222
[TBL] [Abstract][Full Text] [Related]
10. Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells.
Largeot A; Paggetti J; Broséus J; Aucagne R; Lagrange B; Martin RZ; Berthelet J; Quéré R; Lucchi G; Ducoroy P; Bastie JN; Delva L
Biochim Biophys Acta; 2013 Dec; 1833(12):3054-3063. PubMed ID: 23994619
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells.
Paggetti J; Largeot A; Aucagne R; Jacquel A; Lagrange B; Yang XJ; Solary E; Bastie JN; Delva L
Oncogene; 2010 Sep; 29(36):5019-31. PubMed ID: 20581860
[TBL] [Abstract][Full Text] [Related]
12. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2.
Liang J; Prouty L; Williams BJ; Dayton MA; Blanchard KL
Blood; 1998 Sep; 92(6):2118-22. PubMed ID: 9731070
[TBL] [Abstract][Full Text] [Related]
13. STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.
Tam WF; Hähnel PS; Schüler A; Lee BH; Okabe R; Zhu N; Pante SV; Raffel G; Mercher T; Wernig G; Bockamp E; Sasca D; Kreft A; Robinson GW; Hennighausen L; Gilliland DG; Kindler T
Cancer Res; 2013 Jan; 73(1):373-84. PubMed ID: 23149921
[TBL] [Abstract][Full Text] [Related]
14. Bivalent interaction of the PZP domain of BRPF1 with the nucleosome impacts chromatin dynamics and acetylation.
Klein BJ; Muthurajan UM; Lalonde ME; Gibson MD; Andrews FH; Hepler M; Machida S; Yan K; Kurumizaka H; Poirier MG; Côté J; Luger K; Kutateladze TG
Nucleic Acids Res; 2016 Jan; 44(1):472-84. PubMed ID: 26626149
[TBL] [Abstract][Full Text] [Related]
15. MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2.
Yin H; Glass J; Blanchard KL
Mol Cancer; 2007 Aug; 6():51. PubMed ID: 17697320
[TBL] [Abstract][Full Text] [Related]
16. MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.
Kindle KB; Troke PJ; Collins HM; Matsuda S; Bossi D; Bellodi C; Kalkhoven E; Salomoni P; Pelicci PG; Minucci S; Heery DM
Mol Cell Biol; 2005 Feb; 25(3):988-1002. PubMed ID: 15657427
[TBL] [Abstract][Full Text] [Related]
17. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia.
Carapeti M; Aguiar RC; Goldman JM; Cross NC
Blood; 1998 May; 91(9):3127-33. PubMed ID: 9558366
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial readout of unmodified H3R2 and acetylated H3K14 by the tandem PHD finger of MOZ reveals a regulatory mechanism for HOXA9 transcription.
Qiu Y; Liu L; Zhao C; Han C; Li F; Zhang J; Wang Y; Li G; Mei Y; Wu M; Wu J; Shi Y
Genes Dev; 2012 Jun; 26(12):1376-91. PubMed ID: 22713874
[TBL] [Abstract][Full Text] [Related]
19. PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2.
Aikawa Y; Katsumoto T; Zhang P; Shima H; Shino M; Terui K; Ito E; Ohno H; Stanley ER; Singh H; Tenen DG; Kitabayashi I
Nat Med; 2010 May; 16(5):580-5, 1p following 585. PubMed ID: 20418886
[TBL] [Abstract][Full Text] [Related]
20. Ring1A and Ring1B inhibit expression of Glis2 to maintain murine
Shima H; Takamatsu-Ichihara E; Shino M; Yamagata K; Katsumoto T; Aikawa Y; Fujita S; Koseki H; Kitabayashi I
Blood; 2018 Apr; 131(16):1833-1845. PubMed ID: 29371181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
